Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper

Breast Cancer Research and Treatment

Volumn 55, Issue 3, 1999, Pages 223-229

  Small Jr , William ^a,d   Molteni, Agostino ^a,b   Kim, Yoon T ^a,c   Taylor, Joann M ^a   Ts'ao, Chung Hsin ^a   Ward, William F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c RESURRECTION MEDICAL CENTER   (United States)

^d NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Captopril; Catalase; Copper; Hydrogen peroxide; Mammary carcinoma cells

Indexed keywords

CAPTOPRIL; CATALASE; CERULOPLASMIN; COPPER; ESTROGEN RECEPTOR; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; IRON SALT; MITOCHONDRIAL ENZYME; OXIDOREDUCTASE; PROGESTERONE RECEPTOR; THYMIDINE; TRANSFERRIN;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL COUNT; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL;

EID: 0032882551     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006233521325     Document Type: Article

References (34)

1. Migdalof BH, Antonaccio MJ, McKinstry DN, Singhvi SM, Lan SJ, Egli P, Kripalani KJ: Captopril: Pharmacology, metabolism, and disposition. Drug Metab Rev 15: 841-869, 1984
2. Burris JF: The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol 35: 337-342, 1995
3. Garg R, Yusef S (for the Collaborative Group on ACE Inhibitor Trials): Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273: 1450-1456, 1995
4. Pfeffer MA, Braunwald E, Moye LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669-677, 1992
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
6. Jackson WE, Holmes DL, Garg SK, Harris S, Chase HP: Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Opthalmol 24: 99-103, 1992
7. Bauer HA, Lametschwandtner A, Steiner M, Bauer HC: Influence of angiotensin converting enzyme inhibitor (captopril) on kidney epithelial cells in vitro: Studies on potassium (86Rb) influx and cellular proliferation. Clin Chim Acta 187: 47-54, 1990.
8. Chen L, Re RN, Prakash O, Mondal D: Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 196: 280-283, 1991
9. Nguyen L, Ward WF, Ts'ao C, Molteni A: Captopril inhibits proliferation of human lung fibroblasts in culture: A potential antifibrotic mechanism. Proc Soc Exp Biol Med 205: 80-84, 1994
10. Reddy MK, Baskaran K, Molteni A: Inhibitors of angiotensin converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 210: 221-226, 1995
11. Nittler T, Stone M, Shroff O, McAuthur C, Veno P, Dobbs L, Brizio-Molteni L, Molteni A: Effect of captopril on the pro liferation of a human salivary gland adenocarcinoma cell line (Abstract). FASEB 12: A811, 1998
12. Small Jr. W, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF: Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 44: 217-224, 1997
13. Zar JH: Biostatistical Analysis. Prentice-Hall, Englewood Cliffs, NJ, 1974, pp 121-181
14. Lipsky PE, Ziff M: The effect of D-penicillamine on mitogen-induced human lymphocyte proliferation: Synergistic inhibition by D-penicillamine and copper salts. J Immunol 120: 1006-1013, 1978.
15. Hammond WP, Miller JE, Starkebaum G, Zweernick HJ, Rosenthal AS, Dale DC: Suppression of in vitro granulocytopoiesis by captopril and penicillamine. Exp Hematol 16: 674-680, 1988
16. Held KD, Biaglow JE: Mechanisms for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells. Radiat Res 139: 15-23, 1994
17. Fernandex LA, Twickler J, Mead A: Neovascularization produced by angiotensin 2. J Lab Clin Med 105: 141-145, 1985
18. LaNoble FAC, Schreurs NHJS, Van Straaten JFM, Rogg H, Strijker-Boudier HA: Evidence for a novel angiotensin II receptor involved in chick embryo chorionallantoic membrane. Am J Physiol 246: R460-R463, 1993
19. Hernandex I, Cowley AW, Lanbard JH, Greene AS: Salt intake and angiotenin II alter microvessel density in the cremaster muscle of normal rats. Am J Phsyiol 263: H8664-H8667, 1992, 1996
20. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP: Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98: 671-679, 1996
21. Roberts NA, Robinson PA: Copper chelates of antirheumatic and anti-inflammotory agents: Their superoxide dismutase-like activity and stability. Br J Rheumatol 24: 128-136, 1985
22. Reguli J, Misik V: Superoxide scavenging by thiol/copper complex of captopril - an EPR spectroscopy study. Free Radical Res 22: 123-130, 1995
23. Jay D, Cuella A, Jay E: Superoxide dismutase activity of the captopril-iron complex. Mol Cell Biochem 146: 45-47, 1995
24. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M: Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: A possible role for angiotensin II. Atherosclerosis 107: 71-84, 1994
25. Clearfield MB, Lee N, Armstrong L, DeFazio P, Kudehodkar BJ, Lacko AG: The effect of captopril on the oxidation of plasma lipoproteins. Pharmacol Toxicol 75: 218-221, 1994
26. Zieden B, Wuttge DM, Karlberg BE, Olsson AG: Effects of in vitro addition of captopril on copper-induced low density lipoprotein oxidation. Br J Clin Pharmacol 39: 201-203, 1995
27. de Cavanagh EM, Inserra F, Ferder L, Romano L, Ercole L, Fraga CG: Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett 36: 22-24, 1995
28. Sogaard P, Klausen IC, Rungby J, Faergeman O, Thygesen K: Lipoprotein(a) and oxygen free radicals in survivors of acute myocardial infarction: Effects of captopril. Cardiology 87: 18-22, 1996
29. Lapenna D, DeGioia S, Mezzetti A, Ciofani G, Di Ilio C, Cuccurullo F: The prooxidant properties of captopril. Biochem Pharmacol 50: 27-32, 1995
30. Clapperton M, Beswick PH, Abdullah I, Dargie HJ, Fisher AC, McMurray J: Effect of captopril, enalaprilat and mercaptopropionyl glycine (MPG) on the oxidative activity of human isolated neutrophils. Br J Clin Pharmacol 40: 31-35, 1995
31. Bagchi D, Prasad R, Das DK: Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem Biophys Res Comm 158: 52-57, 1989
32. Chopra M, Scott N, McMurray J, McLay J, Bridges A, Smith WE, Belch JJF: Captopril: A free radical scavenger. Br J Clin Pharmacol 27: 396-399, 1989
33. Mak IT, Freedman AM, Dickens BF, Weglicki WB: Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 40: 2169-2175, 1990
34. Aruoma OI, Akanmu D, Cecchini R, Halliwell B: Evaluation of the ability of the angiotensin-converting enzyme inhibitor captopril to scavenge reactive oxygen species. Chem-Biol Interactions 77: 303-314, 1991